Cargando…
A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma
BACKGROUND: Targeting PLK1 has recently been proven as a viable therapeutic strategy against oesophageal squamous cell carcinom (ESCC). Therefore, this study aimed to explore whether the PLK1 inhibitor BI2536 is able to sensitize ESCC cells to cisplatin (DDP) and determine the underlying mechanisms....
Autores principales: | Wu, Mengjiao, Wang, Yan, Yang, Di, Gong, Ying, Rao, Feng, Liu, Rui, Danna, Yeerken, Li, Jinting, Fan, Jiawen, Chen, Jie, Zhang, Weimin, Zhan, Qimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442225/ https://www.ncbi.nlm.nih.gov/pubmed/30876762 http://dx.doi.org/10.1016/j.ebiom.2019.02.012 |
Ejemplares similares
-
Corrigendum to “A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma” [EBioMedicine 41 (2019) 244–255]
por: Wu, Mengjiao, et al.
Publicado: (2019) -
Corrigendum to “A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma” [EBioMedicine 41 (2019) 244–255]
por: Wu, Mengjiao, et al.
Publicado: (2021) -
Defect of SLC38A3 promotes epithelial-mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma
por: Liu, Rui, et al.
Publicado: (2020) -
PFKP is transcriptionally repressed by BRCA1/ZBRK1 and predicts prognosis in breast cancer
por: Yeerken, Danna, et al.
Publicado: (2020) -
Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC)
por: Chen, Jie, et al.
Publicado: (2021)